4
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Childhood non-Hodgkin's lymphoma: A review of treatment results in 53 children

, , &
Pages 213-223 | Received 16 Jul 1984, Accepted 07 Nov 1984, Published online: 09 Jul 2009
 

Abstract

Fifty-three patients, 2 to 18 years old with histologically proven non-Hodgkin's lymphoma (NHL) were treated with combined chemotherapy and involved or extended field irradiation between 1975 and 1982. The disease was classified as undifferentiated Burkitt's type (24), large cell (histiocytic) type (12), lymphoblastic type (13), and undifferentiated non-Burkitt's type (4). Doses of radiation ranged from 1500 to 4000 cGy with an average of 3000 cGy. Disease-free survival at 2 years was: large cell type 9 out of 12 (75%), lymphoblastic 6/13 (46%), undifferentiated non-Burkitt's 1/4 (25%), and Burkitt's lymphoma 12/24 (50%). Bone marrow and/or cerebrospinal fluid relapses continue to be major roadblocks to the successful treatment of childhood non-Hodgkin's lymphoma. Improved success in treatment will depend upon the development of better strategies designed to prevent the occurrence or recurrence of central nervous system (CNS) lymphoma and of more effective systemic therapy. The potential role of radiation therapy in these treatment strategies, especially as regards its use for CNS treatment, should be carefully considered. Chemotherapy, childhood, non-Hodgkin's lymphoma, radiation therapy

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.